Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hematologic Malignancies
•
Medical Oncology
•
Leukemia
•
Hematology
Do you routinely include bone marrow examination in your initial evaluation of a patient with chronic myeloid leukemia?
Related Questions
How would you manage a patient with polycythemia and MPN symptoms (aquagenic pruritus, fatigue) that is JAK2/CALR/MPL negative but peripheral blood NGS positive for IDH2?
What induction regimen would you consider for KMT2A-rearranged AML in a young patient with multiple medical co-morbidities who is ineligible for clinical trials?
What are your top takeaways in Hematologic Malignancies from ASH 2024?
Does treating CLL reduce the risk of non-melanoma skin cancers?
What is your preferred first-line treatment regimen for patients with high-risk MDS?
What is your approach to management of relapsed/refractory T-cell prolymphocytic leukemia (T-PLL)?
How would you treat a patient with selective IgM deficiency on IVIG infusions with a new diagnosis of CLL?
Would you give GO and/or a FLT3 inhibitor for patients with AML with t(8;21) and FLT3-ITD low in addition to 7+3?
In patients with Philadelphia-negative ALL who are transplant ineligible, is there any data to guide the duration of maintenance POMP therapy?
What would be an appropriate frontline AML regimen for transplant ineligible patients with chronic kidney disease (creatinine 2.5 or higher)?
